Behzad Hajari

[ASHM @ASHMMedia]

1/2 Recognise the achievements and uplift an emerging leader working in the #BBV, #STI, or sexual and reproductive health sector with the 2024 Levinia Crooks Emerging Leader Award.

Nominate an early-to-mid career professional now: https://t.co/I9bqVh050C

[NDARC, UNSW @NDARCNEWS]

Can you help us?

We are looking for data for our global #prison review examining #bloodborne virus infections, drug use and harm reduction services among #incarcerated people.

📥 Please get in touch with us at [email protected]

[INHSU @INHepSU]

Join #INHSUEMCR & @CHERISHresearch for a webinar with @ali_jalali_ & @ShashiKapadiaMD. Learn:

➡️Purpose & approach to economic evaluations
➡️Best practices for determining intervention costs
➡️ Approaches to estimating cost-effectiveness

Register: https://t.co/2oGtfLZdY3

[Dr Daniela van Santen @DanielavSanten]

Interested in #HCV elimination, and in particular the role of reinfection? read more about it in this paper!

Very happy to have been able to contribute to this work with such amazing colleagues 🤓

[Jason Grebely @jasongrebely]

Great to see this paper in press @LancetGastroHep Amazing leadership from Alison Marshall @KirbyInstitute to pull together this network. Thanks to our global collaborators, including John Ward & Lindsey Hiebert-Suwondo @GlobalHep, @JVLazarus, Andrew Scheibe, & Peter Vickerman

[Jane Davies @JaneDDarwin]

Amazing work - massive congrats Hep B PAST team 🎉🎉🎉

[Kirby Institute, UNSW @KirbyInstitute]

Globally, only 49% of people who inject drugs were tested for HIV & 47% for hepatitis C. Study by @KirbyInstitute @NDARCNEWS in @LancetGH showed low testing & treatment uptake in this population in most countries. Strategies to improve access are required: https://t.co/VBUIUXiSMI

[Carla Treloar @carlatreloar]

Our new paper - open access!

Views of key informants on evidence and targets to achieve hepatitis C elimination goals in Australia
@LiseLafferty @JoanneBryant14 Jake Rance

https://t.co/egL0cMBOUE

[Behzad Hajari @BehzadHajari]

@AndrewGrulich Congratulations! Very well deserved.

[Behzad Hajari @BehzadHajari]

@HansfordLouise @INHepSU @UNSW @KirbyInstitute @hcvpoct @HepAus @HCVAction @NO_hep @GlobalHepSummit @GlobalHep @TheLancet Thank you indeed, Louise!

[INHSU @INHepSU]

Join @BehzadHajari at #INHSU2023 for a presentation on "Global, regional, and country-level coverage of testing and treatment for #HIV and #HCV infection among people who inject drugs: a systematic review."

Plenary abstract speakers now announced: https://t.co/t5pcEP0ynn

[Kirby Institute, UNSW @KirbyInstitute]

🌟 We're proud to present our 2022 Annual Report. 🌟
In 2022, our team of passionate researchers contributed significant, impactful discoveries to improve health and save lives.

Read the report now: https://t.co/0NVhtzsF8w

[Behzad Hajari @BehzadHajari]

Our study @KirbyInstitute @UNSWMedicine demonstrated that 9% of people with #HCV in 🇦🇺 discontinued therapy (6% in 2016 to 15% in 2021). This📈corresponds to expanding therapy to more marginalized people & highlights needs for access to adherence support & retreatment. @gregdore2

[Elliot Tapper @ebtapper]

Important: more people are stopping hepatitis C treatment early in a Nationwide study from Australia

Some will have been cured by the time they stop. Many may not. It means we need good follow-up, short-duration treatments

https://t.co/Ld1D7KZer8 #livertwitter

[Kirby Institute, UNSW @KirbyInstitute]

Join us this coming Tuesday to hear the fascinating history of hepatitis A, B and C from Dr Michelle Bootcov @mishtory 📅 1pm AEST, Tue 2 May | In-person and online | Free
🎫 Registrations essential: https://t.co/1hMGHGndzN
🗣️ Event page: https://t.co/m6vetIQpSv

[Rebecca Winter @Rebewinter]

Latest global estimates on HIV, HCV Ab/RNA testing coverage among people who inject drugs presented by ⁦⁦@BehzadHajari⁩ #HR23

[Jason Grebely @jasongrebely]

New global data on #HCV and #HIV testing/treatment among PWID presented by @BehzadHajari @KirbyInstitute from study in collaboration with @NDARCNEWS at #HR23 @HRInews. Demonstrates continued low uptake of HCV/HIV testing/treatment globally. Interventions needed to enhance uptake.

[Behzad Hajari @BehzadHajari]

Among people who inject drugs globally, an estimated 15% are living with #HIV and 39% are living with #HCV, @jasongrebely presented in the @HRInews #HR23
@KirbyInstitute @NDARCNEWS

[INHSU @INHepSU]

WEBINAR: Hear from authors of top-ranked research papers from #INHSUPrisons2022 Bibliography

📣 Speakers @jack_stone22, Timothy Papaluca @StVincentsMelb, Joanne Carson @KirbyInstitute
📣 Moderators Nadine Kronfli @mcgillu @Juliasheehan11 @HepatitisCTrust

https://t.co/t5EuEUxXP4

[Samantha Colledge-Frisby (PhD) @SamanthaColled1]

Proud of our team for publishing 2 systematic reviews in the Lancet Glob Health on the prevalence of injecting drug use and the coverage of harm reduction interventions for PWID https://t.co/fHEd8Ue3RB
https://t.co/81nRRwE9Bq

[Behzad Hajari @BehzadHajari]

@BHCHP team: (@maggiebeiser @_LeahCShaw) demonstrated an #HCV reinfection rate of 12/100 PY in people experiencing homelessness. It highlights the importance of post-treatment care for early detection & retreatment of reinfection.